XML 53 R32.htm IDEA: XBRL DOCUMENT v3.20.4
Revenues (Tables)
 12 Months Ended
Dec. 31, 2020
Revenue from Contract with Customer [Abstract]  
Disaggregation of revenue by product and by geographic area
Revenues were as follows (in millions):
Year ended December 31, 2020Year ended December 31, 2019Year ended December 31, 2018
U.S.ROWTotalU.S.ROWTotalU.S.ROWTotal
Enbrel® (etanercept)
$4,855 $141 $4,996 $5,050 $176 $5,226 $4,807 $207 $5,014 
Prolia® (denosumab)
1,830 933 2,763 1,772 900 2,672 1,500 791 2,291 
Neulasta® (pegfilgrastim)
2,001 292 2,293 2,814 407 3,221 3,866 609 4,475 
Otezla®(1)
1,790 405 2,195 139 39 178 — — — 
XGEVA® (denosumab)
1,405 494 1,899 1,457 478 1,935 1,338 448 1,786 
Aranesp® (darbepoetin alfa)
629 939 1,568 758 971 1,729 942 935 1,877 
KYPROLIS® (carfilzomib)
710 355 1,065 654 390 1,044 583 385 968 
Repatha® (evolocumab)
459 428 887 376 285 661 358 192 550 
Other products4,306 2,268 6,574 3,511 2,027 5,538 4,035 1,537 5,572 
Total product sales(2)
17,985 6,255 24,240 16,531 5,673 22,204 17,429 5,104 22,533 
Other revenues511 673 1,184 693 465 1,158 929 285 1,214 
Total revenues$18,496 $6,928 $25,424 $17,224 $6,138 $23,362 $18,358 $5,389 $23,747 

____________
(1)    Otezla® was acquired on November 21, 2019.
(2)    Hedging gains and losses, which are included in product sales, were not material for the years ended December 31, 2020, 2019 and 2018.
Revenues earned from major customers Certain information with respect to these customers was as follows (dollar amounts in millions):
Years ended December 31,
202020192018
AmerisourceBergen Corporation:
Gross product sales$14,743 $12,301 $12,091 
% of total gross revenues34 %33 %33 %
McKesson Corporation:
Gross product sales$13,779 $11,795 $11,434 
% of total gross revenues32 %31 %31 %
Cardinal Health, Inc.:
Gross product sales$7,332 $6,538 $7,475 
% of total gross revenues17 %17 %20 %